OVITRELLE 250mcg Price

Overview

Welcome to Dwaey, specifically on OVITRELLE 250mcg Injection/Solution for page.
This medicine contains an important and useful components, as it consists of Choriogonadotropin alfa.
OVITRELLE 250mcg is available in the market in concentration 250mg/Syringe and in the form of Injection/Solution for.

INDUSTRIA PHARMACEUTICA SERONO S.p.A. is the producer of OVITRELLE 250mcg and it is imported from ITALY, The most popular alternatives of OVITRELLE 250mcg are listed downward .

Mode Of Action

Choriogonadotropin alfa is a recombinant form of chorionic gonadotrophin. Its effects mimic those of leuteinizing hormone, which triggers ovulation and formation of the corpus luteum in women and stimulates the production of testosterone by the testes in men.

Indication

• Anovulatory infertility
• Adjunct to IVF procedures and other assisted conception techniques

Precaution

Asthma, epilepsy, migraine, CV disorders, renal disorders; infertility caused by hyperprolactinaemia, pituitary or hypothalamic tumors; clinically significant systemic diseases where pregnancy could exacerbate the condition. Monitor carefully estradiol levels and ovarian response based on ultrasound prior to and during stimulation therapy. Multiple pregnancy. Lactation: Not known if distributed in breast milk; use caution

Side Effects

• 1-10% Ovarian cyst (3%)
• Ovarian hyperstimulation (2-3%)
• Abdominal pain (3-4%)
• Nausea (3%)
• Vomiting (3%)
• Injection site inflammation (<2%) <1% Breast pain
• Cervical lesion
• Cough
• Albuminuria
• Back pain
• Breast pain
• Cardiac arrhythmia
• Dizziness
• Emotional lability
• Genial herpes
• Hyperglycemia
• Pruritus
• Urinary tract infection
• Vaginal hemorrhage
• Vaginitis Frequency Not Defined Headache
• Irritability
• Depression
• Edema
• Restlessness
• Gynecomastia
• Precocious puberty
• Fatigue
• Arterial thrombus
• Ovarian hyperstimulation syndrome

Contra indication

Ovarian enlargement or cyst (unless caused by polycystic ovarian disease); ectopic pregnancy in previous 3 months; active thromboembolic disorders; hypothalamus, pituitary, ovarian, uterine or mammary malignancy; gynaecological haemorrhage of unknown etiology; primary ovarian failure; sexual organ malformations and fibroid uterine tumors incompatible with pregnancy; postmenopausal women. Uncontrolled thyroid or adrenal dysfunction. Pregnancy and lactation.

Pregnancy and lactation

Pregnancy category: X

Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.